Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments. In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs. Autoimmune Market Outlook to 2012 is a new report examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential. This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market.

Table of Contents
Autoimmune Market Outlook to 2012
Executive Summary 12
Patient potential 12
Global market analysis 13
Pipeline analysis 14
Competitive landscape 15

Chapter 1 Epidemiology of the autoimmune therapeutic area 18
Summary 18
Introduction 19
Osteoarthritis and rheumatoid arthritis 20
Overview 20
Diagnosis, treatment and management 21
Epidemiology 22
Forecast epidemiology 23
Spondyloarthropathies 26
Overview 26
Diagnosis, treatment and management 29
Epidemiology 30
Forecast epidemiology 31
Lupus 35
Overview 35
Diagnosis, treatment and management 36
Epidemiology 37
Forecast epidemiology 39
Psoriasis 40
Overview 40
Diagnosis, treatment and management 41
Epidemiology 43
Forecast epidemiology 44
Crohn’s disease 46
Overview 46
Diagnosis, treatment and management 46
Epidemiology 47
Forecast epidemiology 50

Chapter 2 Global market analysis 54
Summary 54
Introduction 55
Market analysis by country 55
Licensing/generics trends 56
Market analysis by drug class 57
Leading brands dynamics 60
Key events in the autoimmune market 63
Immunosuppressants 65
Competitive dynamics of immunosuppressants 65
Leading brands of immunosuppressants 65
Key brands analysis 68
Immunosuppressants sales forecasts to 2012 77
Antirheumatic agents 78
Competitive dynamics of antirheumatic agents 78
Leading brands of antirheumatic agents 78
Key brands analysis 83
Antirheumatic sales forecasts to 2012 93
NSAIDs 94
Competitive dynamics of NSAIDs 94
Leading brands of NSAIDs 95
Key brands analysis 97
NSAIDs sales forecasts to 2012 101
Topical antirheumatics 102
Competitive dynamics of topical antirheumatics 102
Leading brands of topical antirheumatics 102
Topical antirheumatic sales forecasts to 2012 106
COX-II inhibitors 107
Competitive dynamics of COX-II inhibitors 107
Leading brands of COX-II inhibitors 108
Key brands analysis 110
COX-II inhibitors sales forecasts to 2012 118
Corticosteroids 119
Competitive dynamics of corticosteroids 119
Leading brands of corticosteroids 121
Corticosteroids sales forecasts to 2012 124
Total autoimmune sales forecasts to 2012 125

Chapter 3 Pipeline analysis 128
Summary 128
Introduction 129
Key trends in R&D 129
Biologics 129
Combination drugs 130
Fully human monoclonal antibodies 131
B-cell depleting therapies 131
The autoimmune pipeline 132
Leading drugs in development 134
Profiles of key pipeline products 134
Phase III compounds 134
Licofelone (ML3000) 134
Cimzia (certolizumab pegol) 137
LymphoStat-B (belimumab) 140
Golimumab (CNTO 148) 142
R1594 / PRO70769 (ocrelizumab) 144
Recently marketed drugs 146
Actemra (tocilizumab) 146
Rituxan (rituximab) 148
Taclonex (calcipotriene/betamethasone) 150
Panaclar/BG-12 152
Pipeline forecasts 154
Factors affecting forecasts 154
Autoimmune pipeline forecasts 154

Chapter 4 Competitive landscape 158
Summary 158
Introduction 159
Amgen 163
Overview 163
Sales focus by drug class 163
Marketed product portfolio 164
R&D pipeline analysis 165
Strategic and growth analysis 166
Drivers of growth 166
Resistors of growth 166
Johnson & Johnson 167
Overview 167
Sales focus by drug class 167
Marketed product portfolio 168
R&D pipeline analysis 169
Strategic and growth analysis 170
Drivers of growth 170
Resistors of growth 171
Pfizer 172
Overview 172
Sales focus by drug class 172
Marketed product portfolio 173
R&D pipeline analysis 174
Strategic and growth analysis 175
Drivers of growth 175
Resistors of growth 176
Novartis 177
Overview 177
Sales focus by drug class 177
Marketed product portfolio 178
R&D pipeline analysis 180
Strategic and growth analysis 181
Drivers of growth 181
Resistors of growth 181
Abbott 183
Overview 183
Sales focus by drug class 183
Marketed product portfolio 184
R&D pipeline analysis 185
Strategic and growth analysis 186
Drivers of growth 186
Resistors of growth 186
Wyeth 188
Overview 188
Sales focus by drug class 188
Marketed product portfolio 189
R&D pipeline analysis 191
Strategic and growth analysis 192
Drivers of growth 192
Resistors of growth 192
Roche 193
Overview 193
Sales focus by drug class 193
Marketed product portfolio 194
R&D pipeline analysis 195
Strategic and growth analysis 197
Drivers of growth 197
Resistors of growth 197
Astellas 198
Overview 198
Sales focus by drug class 198
Marketed product portfolio 199
R&D pipeline analysis 200
Strategic and growth analysis 201
Drivers of growth 201
Resistors of growth 201
Boehringer Ingleheim 202
Overview 202
Sales focus by drug class 202
Marketed product portfolio 203
R&D pipeline analysis 204
Strategic and growth analysis 205
Drivers of growth 205
Resistors of growth 205
Schering-Plough 206
Overview 206
Sales focus by drug class 206
Marketed product portfolio 207
R&D pipeline analysis 208
Strategic and growth analysis 208
Drivers of growth 208
Resistors of growth 209

Chapter 5 Appendix 212
IMS data 212
L4A0 Immunosuppressive agents 212
M1A1 Antirheumatics, non-steroidal plain 212
M1A2 Antirheumatics, non-steroidal combination 212
M1A3 Coxibs 212
M1B0 Antirheumatics, steroidal combination 212
M1C0 Specific anti-rheumatic agents 212
M2A0 Antirheumatics, topical 212
Index 213

List of Figures
Figure 1.1: Typical treatment patterns in the treatment of psoriasis 42
Figure 2.2: Global autoimmune market share by geography, 2006 55
Figure 2.3: Sales of types of autoimmune brands, 2005-06 56
Figure 2.4: Competitive dynamics of the global autoimmune market by drug class, 2006 59
Figure 2.5: Competitive dynamics of the leading 10 brands in the global autoimmune market, 2005-06 62
Figure 2.6: Competitive dynamics of the leading immunosuppressant treatments in the global autoimmune market, 2005-6 68
Figure 2.7: Competitive dynamics of the leading antirheumatic treatments in the global autoimmune market, 2005-6 82
Figure 2.8: Competitive dynamics of the leading NSAID treatments in the global autoimmune market, 2005-06 97
Figure 2.9: Competitive dynamics of the leading topical antirheumatic treatments in the global autoimmune market, 2005-06 105
Figure 2.10: Competitive dynamics of the leading COX-II treatments in the global autoimmune market, 2005-6 110
Figure 2.11: Competitive dynamics of the leading corticosteroid treatments in the global autoimmune market, 2005-06 123
Figure 3.12: Prevailing R&D approaches, 2006 129
Figure 3.13: The autoimmune pipeline by indication and stage of development, 2006 132
Figure 3.14: Leading recently launched products and late-stage R&D compounds indicated for the treatment of autoimmune disorders, 2006 134
Figure 4.15: Competitive dynamics of the leading players in the global autoimmune market, 2006 162
Figure 4.16: Amgen’s auto-immune sales, 2006 163
Figure 4.17: J&J’s autoimmune sales, 2006 167
Figure 4.18: Pfizer’s autoimmune sales, 2006 172
Figure 4.19: Novartis’ autoimmune sales by drug class, 2006 177
Figure 4.20: Abbott’s autoimmune sales by drug class, 2006 183
Figure 4.21: Wyeth’s autoimmune sales by drug class, 2006 188
Figure 4.22: Roche’s autoimmune sales by drug class, 2006 193
Figure 4.23: Astellas’ autoimmune salesby drug class, 2006 198
Figure 4.24: BI’s autoimmune salesby drug class, 2006 202
Figure 4.25: Schering-Plough’s autoimmune sales by drug class, 2006 206

List of Tables
Table 1.1: Estimated prevalence of autoimmune-related diseases in the seven major pharmaceutical markets, 2006 19
Table 1.2: Estimated prevalence of osteoarthritis across the seven major pharmaceutical markets, 2006 22
Table 1.3: Estimated prevalence of rheumatoid arthritis across the seven major pharmaceutical markets, 2006 23
Table 1.4: Forecast prevalence of OA across the seven major markets, 24
Table 1.5: Forecast prevalence of RA across the seven major markets, 25
Table 1.6: Estimated prevalence of ankylosing spondylitis across the seven major pharmaceutical markets, 2006 31
Table 1.7: Estimated prevalence of psoriatic arthritis across the seven major pharmaceutical markets, 2006 32
Table 1.8: Forecast prevalence of ankylosing spondylitis across the seven major markets, 2006–12 33
Table 1.9: Forecast prevalence of psoriatic arthritis across the seven major markets, 2006–12 34
Table 1.10: Estimated prevalence of lupus across the seven major pharmaceutical markets, 2006 37
Table 1.11: Forecast prevalence of lupus across the seven major markets, 2006–12 39
Table 1.12: Estimated prevalence of psoriasis across seven major markets, 2006 44
Table 1.13: Forecast prevalence of psoriasis across the seven major markets, 2006-12 45
Table 1.14: Estimated prevalence of Crohn’s disease in the seven major pharmaceutical markets, 2006 48
Table 1.15: Forecast prevalence of Crohn’s disease across the seven major markets, 2006–12 50
Table 2.16: Breakdown of the global autoimmune market by drug class, 2002-06 58
Table 2.17: Leading brands in the global autoimmune market, 2005–06 60
Table 2.18: Leading immunosuppressant brands in the global autoimmune market, 2005–06 66
Table 2.19: Immunosuppressive agents sales forecast, 2006-12 77
Table 2.20: Leading antirheumatic brands in the global autoimmune market, 2005–06 79
Table 2.21: Antirheumatics sales forecast, 2006-12 93
Table 2.22: Leading NSAID brands in the global autoimmune market, 2005–06 95
Table 2.23: NSAIDs sales forecast, 2006-12 101
Table 2.24: Leading topical antirheumatic brands in the global autoimmune market, 2005–06 103
Table 2.25: Topical antirheumatic sales forecast, 2006-12 106
Table 2.26: Leading COX-II brands in the global autoimmune market, 2005–06 108
Table 2.27: COX-II inhibitors sales forecast, 2006-12 118
Table 2.28: Leading corticosteroids brands in the global autoimmune market, 2005–06 121
Table 2.29: Corticosteroids sales forecast, 2006-12 124
Table 2.30: Therapeutic sales forecasts by drug class, 2006-112 125
Table 3.31: Autoimmune pipeline sales forecasts, 2006-12 154
Table 4.32: Leading players in the global autoimmune market, 2005-06 159
Table 4.33: Amgen’s autoimmune product portfolio, 2004-05 164
Table 4.34: Amgen’s autoimmune R&D product pipeline, 2006 165
Table 4.35: J&J’s autoimmune product portfolio, 2005-06 168
Table 4.36: J&J’s autoimmune R&D product pipeline, 2006 169
Table 4.37: Pfizer’s autoimmune product portfolio, 2005-06 173
Table 4.38: Pfizer’s auto immune R&D product pipeline, 2006 175
Table 4.39: Novartis’ autoimmune product portfolio, 2005-06 178
Table 4.40: Novartis’ autoimmune R&D product pipeline, 2006 180
Table 4.41: Abbott’s autoimmune product portfolio, 2005-06 184
Table 4.42: Abbott’s autoimmune R&D product pipeline, 2006 185
Table 4.43: Wyeth’s autoimmune product portfolio, 2005-06 189
Table 4.44: Wyeth’s autoimmune R&D product pipeline, 2006 191
Table 4.45: Roche’s autoimmune product portfolio, 2005-06 194
Table 4.46: Roche’s autoimmune R&D product pipeline, 2006 195
Table 4.47: Astellas’ autoimmune product portfolio, 2005-06 199
Table 4.48: Astellas’ autoimmune R&D product pipeline, 2006 200
Table 4.49: BI’s autoimmune product portfolio, 2005-06 203
Table 4.50: BI’s autoimmune R&D product pipeline, 2006 204
Table 4.51: Schering-Plough’s autoimmune product portfolio, 2005-06 207
Table 4.52: Schering-Plough’s autoimmune R&D product pipeline, 2006 208